The poultry industry sustains significant losses each year due to coccidiosis. Young birds are especially vulnerable to pathogenic infections as it takes several months for their immune systems to mature after birth. Prevention of coccidiosis can be achieved with drugs that either kill the parasites or prevent their growth and replication within the gastrointestinal tract. The use of anticoccidial medicines has led to drug-resistant strains, therefore, Elanco is searching for novel approaches to prevent, treat, or control coccidiosis in poultry.
A webinar presented by Elanco and InnoCentive concerning Elanco’s Grand Challenge Program was held on October 20, 2016. A recording of the session can be accessed here.
This Theoretical Challenge requires only a written proposal.
Although coccidia are ubiquitous in poultry flocks, coccidiosis occurs only after the ingestion of a large number of sporulated oocysts of Eimeria. Lesions can appear throughout the intestines whereas the particular location and the pathological presentation of disease are correlated with different species of the parasite. Outward signs of disease include a ruffled appearance, weight loss, diarrhea, and mortality. Anticoccidial drugs are the mainstay of coccidiosis prevention and have been used successfully by poultry producers for decades, yet the consequence of such widespread use is the development of drug resistance. Therefore, Elanco is searching for novel approaches to prevent, treat, or control coccidiosis in poultry.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer to the Seeker their exclusive intellectual property (IP) rights to the solution.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 29, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
Elanco provides comprehensive products and knowledge solutions to improve animal health and to produce wholesome food in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food safety, food security, and celebrating and supporting the human-animal bond. Elanco has committed to an 8-step Antibiotic Stewardship Plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use, and replaces antibiotics with alternatives. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.